Aura Announces Strategic Entry Into the European Market With the Closing of the Acquisition of Pharmadrug
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has closed the previously announced (May 8, 2019) acquisition of an 80% equity interest in Pharmadrug Production GmbH (“Pharmadrug”) for total consideration of €5.0 million. Pharmadrug is a cash flow positive German pharmaceutical distribution company with over 20 years of operating history and a Schedule I European Union narcotics license allowing for the distribution of medical cannabis to pharmacies in Germany and throughout the Eurozone as markets become legalized. Pharmadrug has supply agreements in place with Bedrocan International B.V., Canadian Licensed Producers, and is currently supplying medical cannabis to pharmacies in Germany.
Daniel Cohen, CEO of Aura, commented, “This is a historic day in the early life of Aura, having closed on our first flagship transaction. This acquisition establishes Aura in the European market as a medical cannabis supplier in Germany and opens doors to opportunities throughout the rest of the continent. Pharmadrug is a strong strategic fit with our Israel cultivation project and the opening of the Israeli export law. We now have a strategic avenue to export our own medical cannabis from Israel into the European Union. In addition, we plan to significantly grow the Pharmadrug business through additional supply agreements with other Canadian, Israeli, and European LPs.”
The Company has satisfied the escrow release conditions pursuant to its previously announced private placement of a cumulative amount of 21,545,454 subscription receipts (each, a “Subscription Receipt”) at a price of $0.22 per Subscription Receipt for gross proceeds of approximately $4.74 million and has successfully drawn $3 million from its previously announced bridge facility (see the press release issued by Aura on May 8, 2019).
Resignation of Mr. Freudman
Aura also announces that Joel Freudman has resigned as a director in order to focus on his other business ventures. Aura thanks Mr. Freudman for his corporate governance advice while also helping the Company through its first audit as a publicly-traded company. The Company is in discussions with other qualified candidates to replace Mr. Freudman and will be making an announcement once such replacement has been confirmed.
About Aura Health Inc.
Aura Health is building an international network of vertically integrated cannabis assets. Through an established product line of cannabis-infused edible products and oil extracts, Aura is dedicated to building a high margin downstream business in the medical marijuana sector. The Company owns 80% of Pharmadrug, a German medical cannabis and pharmaceutical distributor, as well as debt that converts to 54% equity of HolyCanna, a cultivation and nursery license holder in Israel. Aura also has a binding letter of intent to purchase CannabiSendak, the builder of a network of high-profile dispensaries in Israel.
For further information, please contact:
Daniel Cohen, CEO
Aura Health Inc.
(647) 202-1824
David Posner, Chairman
Aura Health Inc.
(647) 985-6727
Caution Regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of Pharmadrug or Aura. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include reference to Aura’s expansion through Europe, and the entering into of additional supply agreements, among others. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals, owning interests in companies or projects that are engaged in activities currently considered illegal under United States federal law; changes in laws; limited operating history, reliance on management, requirements for additional financing, competition, hindering market growth; regulatory and political change.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Click here to connect with Aura Health Inc. (CSE:BUZZ) for an Investor Presentation.
Source: www.globenewswire.com
Matica Enterprises Inc. (CSE:MMJ) (OTCQB:MMJFF) (39N – Frankfurt) (“Matica” or the “Company”) is pleased to announce the completion of the first cannabis harvest at the Dorval facility of RoyalMax Biotechnology Canada Inc. (“RoyalMax”). This is an important milestone for RoyalMax and Matica as the companies move towards retail and medical sales licensing.
“Our team, working in a state of the art facility, is producing the type of high quality product the market is demanding. This first harvest is important not just for our company but, for Quebec cannabis as a whole. With so few licence holders in the Province, more production of high quality cannabis from Quebec is an absolute must” states Boris Ziger, CEO of Matica, and adds that “I wish to thank our highly committed team and can’t express how proud I am of them.”
With the success of the first harvest, RoyalMax intends to follow up with a successful second harvest in the coming weeks. The third and fourth crops have already been placed in grow rooms populated with clones from our mother room. The facility will soon be running at full capacity with all grow rooms active. At full capacity RoyalMax plans a rotating schedule with harvests every two to three weeks.
About Matica
Matica is a multi-faceted, innovative company in the Quebec cannabis space. RoyalMax Biotechnology Canada Inc. has been granted a standard cultivation licence by Health Canada for the production facility in Dorval, Quebec. Matica intends to build 1,000,000 square feet of greenhouses, in 200,000 square foot increments, on a 181 acre property in the township of Hemmingford, south of Montreal. Matica has entered into an agreement with Yunify Natural Technologies, a Quebec based health and personal care research and innovation company to develop proprietary products for Matica and RoyalMax.
For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.
On behalf of the Board of Directors
MATICA ENTERPRISES INC.
Boris Ziger
Boris Ziger, CEO & Chairman
The Company’s public filings are available for review at www.sedar.com and www.thecse.com.
For further information, please contact Boris Ziger, at:
Telephone: 416-304-9935
E-mail: info@maticaenterprises.com
Website: www.maticaenterprises.com , www.maticammj.com
Suite 1102 – 44 Victoria Street
Toronto, ON, M5C 1Y2
Tel: (416) 304-9935
Disclaimer for Forward-Looking Information
Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.
This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.
Source: www.thenewswire.com
Asterion Cannabis Inc. (P.ASTR) (“Asterion” or the “Company”), announces that it will be attending the Cowen Toronto Cannabis Summit on May 22, 2019 held at The Westin Harbour Castle, Toronto, Canada. Mr. Stephen Van Deventer, Asterion’s Chairman and CEO, has been invited to sit as one of three panelists on the Emerging Cannabis Companies Panel, to discuss Asterion’s domestic and international opportunities.
Mr. Stephen Van Deventer commented, “I am pleased to be representing Asterion as part of the Emerging Cannabis Companies panel, along with representatives of Pyxus International, Inc. and Sundial Growers Inc. Asterion looks forward to participating in interesting discussions about opportunities and trends in this evolving cannabis market space.”
Founded in 1918, Cowen, Inc. is headquartered in New York and has offices worldwide. Cowen hosts 10-15 major industry-specific conferences annually attracting top institutional investors and leading companies in multiple sectors, including health care and technology.
About Asterion
Asterion is a Canadian medicinal cannabis company with operations in Australia, specializing in medical cannabis and is focused on becoming an industry leader in next-generation cannabis products. The Company is focused on the future of precision agriculture and aims to produce the highest quality of genetically uniform cannabis strains, at an affordable price.
The Company is led by a team of highly experienced executives with over 120 years of combined experience in medical cannabis, renewable energy, capital markets, and other highly relevant sectors across North America, Oceania, Europe, Africa and Asia.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman & Chief Executive Officer
For further information, please contact:
Deanna Kress
+1-778-999-6063
info@asterioncannabis.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. Other than statements of historical fact, all statements included in this news release, including, without limitation, statements regarding the Company’s anticipated business plans and prospects of success in executing its plans, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Various risks and uncertainties could cause actual results to differ materially from Asterion’s expectations. Other factors such as general economic, market or business conditions, future prices of cannabis, changes in the financial markets and in the demand and market price for cannabis, or changes in laws, regulations and policies affecting the biotechnology or cannabis industry, and delays in obtaining governmental and regulatory approvals, may also adversely affect the future results or performance of the Company. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
Click here to connect with Asterion Cannabis Inc. for an Investor Presentation.
Source: www.newsfilecorp.com
Transcanna Holdings Inc. (CSE:TCAN) (FSE:TH8) (“TransCanna” or the “Company”) is pleased to announce today the execution of a non-binding Letter of Intent dated May 15, 2019 (“LOI”) with Tres Ojos Naturals, LLC d/b/a SolDaze (“SolDaze”), a limited liability company from Santa Cruz, California, to acquire the branding asset package, Soldaze (the “Assets”). SolDaze produces cannabis-infused fruit snacks in California. For more information on SolDaze product lines, please see their website: www.soldazesnacks.com.
“Having reviewed over 100 branded products in California, we’ve been extremely selective in our acquisition vetting process. Our three mandatory acquisition criteria include SKU velocity, upward trending revenues, and products that differentiate themselves in the marketplace. The snack line from SolDaze, and specifically the cannabis-infused mango products, meets all three requirements,” stated Jim Pakulis, CEO of TransCanna.
“Over the past year, we’ve created a unique line of fruit-based, organic edibles that truly differentiate us in the market. We then began supplying select dispensaries and almost immediately began receiving repeat orders. We’re now at the stage where we need to expand throughout California,” stated Shawn Shevlin, founder and president of SolDaze. “TransCanna’s platform, including the 196,000-square-foot facility; their commitment to supplying the necessary capital for our immediate growth; and their adherence to compliance will provide SolDaze the tools and guidance that are mandatory in order to be successful and scale in California.”
Pursuant to the LOI, the Company would acquire the Assets for a cash payment of USD$350,000 and the issuance of 660,000 common shares in the capital of the Company. A nonrefundable deposit of US$50,000 was paid on the execution of the LOI, to be credited against the purchase price. The purchase price is payable in installments over a two-year period, provided that the timing of such installments may be accelerated should the sales of SolDaze products meet specific revenue targets, and the number of shares issuable may be reduced by up to 37,125 in the event that the revenue targets specified are not met by the dates specified.
The completion of the Asset acquisition remains subject to completion of due diligence and execution of final binding definitive asset purchase documentation, which is to be completed within 45 days of the date of the LOI. There can be no assurances that the completion of the acquisition will occur on the terms set forth above or at all.
For further information, please visit the Company’s website at www.transcanna.com.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a Canadian-based company focused on providing integrated branding, transportation and distribution services, through its wholly owned California subsidiaries, to a range of industries including the cannabis marketplace.
For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.
Media Contact
TransCanna@talkshopmedia.com
604-738-2220
On behalf of the Board of Directors
James Pakulis
Chief Executive Officer
Telephone: (604) 609-6199
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
Click here to connect with Transcanna Holdings Inc. (CSE:TCAN) for an Investor Presentation.
Source: www.newsfilecorp.com
1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE:TGIF) (OTCQX:TGIFF) a licensed cultivator and producer of cannabis flower and concentrates and manufacturer of hemp/CBD wellness products, is pleased to report that Mr. Chris Rebentisch, USA COO and Founder of the Company’s Infused MFG. subsidiary, will present to an investor audience this week in New York during two highly anticipated events in the cannabis industry.
3rd Annual Canaccord Genuity Cannabis Conference
Held on May 14th at the Grand Hyatt New York, the one-day event will feature company presentations and one-on-one meetings with senior management teams representing every facet of the global cannabis industry, including U.S. multi-state operators, Canadian licensed producers, technology providers, brand owners and hemp producers from across North America, Europe, Australia and South America.
Mr. Rebentisch’s formal presentation is scheduled for 9:20AM and the 1933 Industries team will be available for private meetings throughout the day. For more information, please visit https://www.canaccordgenuity.com/capital-markets/about-us/events/
CannaStocks2019 Q1 Investor Conference
The Company will also present at the CannaStocks2019 Q1 Investor Conference to be held at the OTC Markets Group offices in New York on May 15th, featuring company presentations and discussions regarding current market trends from a few select OTC Markets QX and QB tier Issuers. Mr. Rebentisch is scheduled to present at 3:00PM.
Industry participants will provide insight on themes including: innovation, consolidation, international expansion and specialization. For those investors unable to attend in person, a live streaming video webcast of the event will be available on the Virtual Investor Conferences, which will also be archived and made available after the event. For more information, please visit www.CannaStocks2019.com
About 1933 Industries Inc.
1933 Industries Inc. is a vertically integrated cannabis company with operations in the United States and Canada. Operating through three subsidiary companies, 1933 Industries owns licensed medical and adult-use cannabis cultivation and production assets, proprietary hemp-based, CBD infused products, CBD extraction services and a specialized cannabis advisory firm supporting clients in security, intelligence and due diligence. The Company owns 91% of Alternative Medicine Association and 100% of both Infused MFG. and Spire Global Strategy.
For further information please contact:
Alexia Helgason, Corporate Communications Director
604-674-4756 (ext. 1)
alexia@1933industries.com
Brayden Sutton, Director/President & CEO
604-674-4756 (ext. 1)
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE: 1933 Industries Inc.
Source: www.accesswire.com
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN), (OTCQB:KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company’s previously announced agreement for the acquisition (the “Acquisition”) of NettaGrowth International Inc. (“NettaGrowth”), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. (“Dormul”), is progressing as planned and the Company is in the latter stages of securing local regulatory approvals in Uruguay for the completion of the Acquisition. The Company has received conditional approval for the Acquisition from the TSX Venture Exchange Inc. (“TSXV”).
At this time, there has been no change to the status of the license applications of Dormul. The parties anticipate completing the Acquisition by the end of June 2019, subject to the satisfaction or waiver of all closing conditions and receipt of all regulatory approvals.
About NettaGrowth and Dormul
NettaGrowth, through Dormul, is a Latin America export focused cannabis company based in Uruguay, and is well positioned to serve Brazil and the growing Latin American market. They will employ the latest growing, extracting and processing technologies to produce high quality medical cannabis products for the Latin American market.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at www.khiron.ca.
To be added to the distribution list, please email khiron@kcsa.com with “Khiron” in the subject line.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the anticipated closing date of the Acquisition and the receipt of all required regulatory approvals, among others. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: cnaprawa@khiron.ca; Phil Carlson, KCSA Strategic Communications T. (212)-896-1233, E: khiron@kcsa.com; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca
Source: www.newswire.ca